0IV3 Stock Chart & Stats
$1.51
-$0.03(-1.71%)
At close: 4:00 PM EDT
$1.51
-$0.03(-1.71%)
Day’s Range― - ―
52-Week Range$0.85 - $2.00
Previous CloseN/A
Volume48.57K
Average Volume (3M)68.79K
Market Cap
$574.63M
Enterprise Value$807.52M
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend Yield7.85%
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume101,642
30 Day Avg. Volume68,792
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit4.74
Enterprise Value/Ebitda-19.52
Forecast
1Y Price Target
$4.00Price Target Upside164.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$235.36M
Bulls Say, Bears Say
Bulls Say
RYTELO Revenue And Adoption GrowthGrowing RYTELO revenue alongside expansion in prescribing accounts indicates increasing commercial adoption in the lower-risk MDS market. Continued demand growth and management’s expectation of reaching the mid- to high-end of 2026 guidance support a developing revenue base over the next several quarters.
Improving Operating LeverageRevenue growth materially outpacing operating-expense growth demonstrates improving operating leverage as the commercial franchise scales. If this relationship persists, it can reduce the cost burden of expansion and provide a clearer path toward improved operating profitability without requiring equivalent increases in spending.
Stronger Capital StructureVery low debt relative to equity gives Geron greater financial flexibility than in the prior year, while its cash and securities provide resources for commercial investment and clinical programs. This stronger capital structure can help support execution through the product’s growth phase and reduce near-term financing pressure.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not yet self-funding despite commercial revenue growth. Continued cash burn can consume financial resources, increase reliance on external funding or balance-sheet reserves, and constrain the company’s ability to invest across commercial and clinical priorities.
Ongoing Net LossesGeron remains unprofitable even as revenue scales, indicating that product growth has not yet covered development, commercial, and corporate costs. Sustained net losses can delay internally generated capital formation and leave future profitability dependent on continued adoption, expense control, and successful operating leverage.
Myelofibrosis Program SetbackDiscontinuing IMpactMF removes a major clinical opportunity from the development portfolio after the study was judged unlikely to meet its primary endpoint. The setback narrows imetelstat’s potential beyond lower-risk MDS, increases reliance on RYTELO execution, and weakens diversification within the pipeline.
Geron News
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $0.85 and its highest was $2.00 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $574.63M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 7.85%. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 16.045%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GB:0IV3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (164.90% Upside)
$4.00 (164.90% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 75%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.90%
12-Months-Change
Fundamentals
Return on Equity
-30.31%
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
0IV3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GB:0IV3 earnings summaries0IV3 Stock 12 Month Forecast
Average Price Target
$4.00
▲(164.90% Upside)